publication date: Dec. 18, 2010

In this issue: 

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

Download (PDF 437KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.